FindTrial
Sign In

TPMT/NUDT15 Preemptive Genotyping to Guide Precision 6-Mercaptopurine Dosing in Chinese Pediatric Patients with Acute Lymphoblastic Leukemia

TPMT/NUDT15 Preemptive Genotyping to Guide Precision 6-Mercaptopurine Dosing in Chinese Pediatric Patients with Acute Lymphoblastic Leukemia: A Multicenter, Prospective, Type II Hybrid Implementation-Effectiveness Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117236
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lymphoblastic leukemia

Interventions

preemptive genetic testing group:N/A
History Group(Post-event testing):N/A

Sponsors

Fujian Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children newly diagnosed with ALL who need 6-MP treatment, aged 1-18 years.

Exclusion criteria

Exclusion criteria: Patients with other malignant tumors combined.

Design outcomes

Primary

MeasureTime frame
dosage;Inpatient stay;infection incidence;Unplanned Readmission;hepatotoxicity;—

Countries

China

Contacts

Public ContactRong Hu

Fujian Children's Hospital

hurong23@alumni.sysu.edu.cn+86 137 1088 0327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026